Johnson & Johnson

NYSE:JNJUnited States

Today

Show headlines and story abstract

• Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: JNJ
  
  Class action lawsuit demands compensation for future talc-related injuries and medical monitoring of talcum powder users
  TRENTON, N.J.--(BUSINESS WIRE)--June 17, 2024--
  Plaintiffs who are at increased risk of ovarian cancer due to long-term use of Johnson & Johnson's Baby Powder have filed a class action lawsuit in New Jersey federal court seeking to hold Johnson & Johnson (NYSE:JNJ) and a number of corporate subsidiaries and executives responsible for future liability and to establish a court-supervised system to monitor the ongoing health condition of talcum powder users.
  

• DJ Johnson & Johnson Price Target Maintained With a $175.00/Share by RBC Capital, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: JNJ
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/JNJ/analyst-ratings
  
  (END) Dow Jones Newswires
  
  June 17, 2024 09:14 ET (13:14 GMT)
  

• Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: JNJ, BMEA, ATNM, KURA, SNDX
  
  Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
  
  PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells. According to Global Market Insights the Acute Myeloid Leukemia Market was valued at USD 2.1 Billion in 2023 and is estimated to grow at a CAGR of 10.7% between 2024 and 2032. High market growth can be attributed to factors such as advancement in research and technology, surging government initiatives and policies, early diagnosis coupled with efforts to implement screening programs. Also, increasing prevalence of acute myeloid leukemia (AML) is a significant factor driving the growth of the market. The report said: "For instance, according to the American Cancer Society, in 2023, there were about 20,380 new cases of acute myeloid leukemia (AML) in the U.S. alone. Hence, as the population ages, the incidence of AML tends to rise, contributing to a larger patient pool seeking diagnosis and treatment, thereby fostering the market growth. Surging government initiatives and polices play a pivotal role in driving the acute myeloid leukemia industry. Also, increased government funding for medical research, including acute myeloid leukemia research, drive advancements in understanding the molecular basis of AML, leading to the
  

• Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer, from 11 hours ago by MT Newswires

  11 hours ago by MT Newswires
  Companies Mentioned: JNJ
  08:51 AM EDT, 06/17/2024 (MT Newswires) -- Johnson & Johnson (JNJ) said Monday that it had submitted a Biologics License Application to the US Food and Drug Administration for subcutaneous amivantamab for certain patients with non-small cell lung ca...

• Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer, from 12 hours ago by Dow Jones

  12 hours ago by Dow Jones
  Companies Mentioned: JNJ
  
  (27) Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.